Tags

Type your tag names separated by a space and hit enter

Radiotherapy for 41 patients with stages I and II MALT lymphoma: a retrospective study.
Radiother Oncol. 2008 Jun; 87(3):412-7.RO

Abstract

PURPOSE

Mucosa-associated lymphoid tissue (MALT) lymphoma is a distinct disease with specific clinical and pathologic features that may affect diverse organs. We analyzed our recent experience with Stage I/II MALT lymphoma presenting in the stomach and other organs to assess the outcome following radiation therapy (RT) alone.

PATIENTS AND METHODS

Forty-one patients with Stages I (37) and II (4) disease were treated between 2000 and 2006. Patients with transformed MALT were excluded. The median age was 60 years (range, 25-86 years), male: female ratio 1:1. Presenting sites included stomach, 11; orbital adnexa, 21; thyroid, 1; other head and neck, 3; small bowel, 3; skin, 1; and rectum, 1. Thirty-five patients (85%) received RT-alone and 6 (15%) received antibiotics followed by RT. RT dose was 30Gy in 20 fractions (fr) in all 41 patients. Mean follow-up time was 32.0 months (range, 2.1-162 months).

RESULTS

A first complete response was achieved in all 41 patients. Only one patient died from bile duct carcinoma at 22 months from the start of irradiation for conjunctiva MALT lymphoma without recurrence of lymphoma. The other 40 patients were alive. Thirty-eight patients out of them were alive without recurrence. One patient with a duodenal lymphoma had a recurrence in non-irradiated distant sites at 1 month. Another patient with a bilateral eye lid lymphoma had a recurrence within radiation field at 41 months. The absolute local control rate with radiation was 98% (40/41 patients).

CONCLUSION

Localized MALT lymphomas have excellent prognosis following moderate-dose RT (30Gy/20fr).

Authors+Show Affiliations

Department of Radiology, University of Tokyo Hospital, Hongo, Bunkyo-ku, Tokyo, Japan.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

18423914

Citation

Yamashita, Hideomi, et al. "Radiotherapy for 41 Patients With Stages I and II MALT Lymphoma: a Retrospective Study." Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology, vol. 87, no. 3, 2008, pp. 412-7.
Yamashita H, Nakagawa K, Asari T, et al. Radiotherapy for 41 patients with stages I and II MALT lymphoma: a retrospective study. Radiother Oncol. 2008;87(3):412-7.
Yamashita, H., Nakagawa, K., Asari, T., Murakami, N., Igaki, H., & Ohtomo, K. (2008). Radiotherapy for 41 patients with stages I and II MALT lymphoma: a retrospective study. Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology, 87(3), 412-7. https://doi.org/10.1016/j.radonc.2008.03.012
Yamashita H, et al. Radiotherapy for 41 Patients With Stages I and II MALT Lymphoma: a Retrospective Study. Radiother Oncol. 2008;87(3):412-7. PubMed PMID: 18423914.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Radiotherapy for 41 patients with stages I and II MALT lymphoma: a retrospective study. AU - Yamashita,Hideomi, AU - Nakagawa,Keiichi, AU - Asari,Takao, AU - Murakami,Naoya, AU - Igaki,Hiroshi, AU - Ohtomo,Kuni, Y1 - 2008/04/16/ PY - 2008/02/08/received PY - 2008/03/14/revised PY - 2008/03/14/accepted PY - 2008/4/22/pubmed PY - 2008/11/6/medline PY - 2008/4/22/entrez SP - 412 EP - 7 JF - Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology JO - Radiother Oncol VL - 87 IS - 3 N2 - PURPOSE: Mucosa-associated lymphoid tissue (MALT) lymphoma is a distinct disease with specific clinical and pathologic features that may affect diverse organs. We analyzed our recent experience with Stage I/II MALT lymphoma presenting in the stomach and other organs to assess the outcome following radiation therapy (RT) alone. PATIENTS AND METHODS: Forty-one patients with Stages I (37) and II (4) disease were treated between 2000 and 2006. Patients with transformed MALT were excluded. The median age was 60 years (range, 25-86 years), male: female ratio 1:1. Presenting sites included stomach, 11; orbital adnexa, 21; thyroid, 1; other head and neck, 3; small bowel, 3; skin, 1; and rectum, 1. Thirty-five patients (85%) received RT-alone and 6 (15%) received antibiotics followed by RT. RT dose was 30Gy in 20 fractions (fr) in all 41 patients. Mean follow-up time was 32.0 months (range, 2.1-162 months). RESULTS: A first complete response was achieved in all 41 patients. Only one patient died from bile duct carcinoma at 22 months from the start of irradiation for conjunctiva MALT lymphoma without recurrence of lymphoma. The other 40 patients were alive. Thirty-eight patients out of them were alive without recurrence. One patient with a duodenal lymphoma had a recurrence in non-irradiated distant sites at 1 month. Another patient with a bilateral eye lid lymphoma had a recurrence within radiation field at 41 months. The absolute local control rate with radiation was 98% (40/41 patients). CONCLUSION: Localized MALT lymphomas have excellent prognosis following moderate-dose RT (30Gy/20fr). SN - 0167-8140 UR - https://www.unboundmedicine.com/medline/citation/18423914/Radiotherapy_for_41_patients_with_stages_I_and_II_MALT_lymphoma:_a_retrospective_study_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0167-8140(08)00160-6 DB - PRIME DP - Unbound Medicine ER -